Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Post-authorization Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration Among Patients Treated With Empagliflozin or DPP-4 Inhibitors in Saudi Arabia
Verified date | February 2022 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract infections, volume depletion, and dehydration associated in patients with T2DM initiating Empagliflozin compared to patient initiating a dipeptidyl peptidase-4 (DPP-4) inhibitors over a 12-month period of follow-up, including the month of Ramadan
Status | Completed |
Enrollment | 1502 |
Est. completion date | January 11, 2021 |
Est. primary completion date | January 11, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who have signed Informed consent form. - The patients will be at least 18 years old at index date, diagnosed with Type 2 diabetes mellitus (T2DM) in Saudi Arabia, and who will initiate Empagliflozin or Dipeptidyl-peptidase 4 (DPP4) inhibitors treatment according to the local label and at the discretion of the treating physician during the study period, who have not used other sodium/glucose co-transporter 2 (SGLT2) or DPP4 inhibitors during the previous 12 months. Exclusion Criteria: - Known hypersensitivity to Empagliflozin, the comparator DPP-4 inhibitors or any of their excipients - Patients for whom Empagliflozin or the comparator DPP-4 inhibitor is contraindicated according Saudi Food and Drug Authority (SFDA) approved label - Patients prescribed fixed-dose combinations of SGLT2 inhibitors with DPP-4 inhibitors will be excluded. - The same inclusion and exclusion criteria will be applied to the comparator group, which will include new users of DPP-4 inhibitors. |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Abha International Private Hospital | Abha | |
Saudi Arabia | Al Abeer Medical Center | Jeddah | |
Saudi Arabia | Al Abeer Polyclinic | Jeddah | |
Saudi Arabia | Al-Abeer Medical Center | Jeddah | |
Saudi Arabia | DAFA Special Polyclinic | Jeddah | |
Saudi Arabia | Dr. Soliman Fakeeh Hospital | Jeddah | |
Saudi Arabia | Dr.Bakhsh Hospital | Jeddah | |
Saudi Arabia | Ghassan Najeeb Pharaon Hospital | Jeddah | |
Saudi Arabia | International Medical Center | Jeddah | |
Saudi Arabia | Saudi German Hospital | Jeddah | |
Saudi Arabia | Al Rahman Polyclinic | Makkah | |
Saudi Arabia | Al-Noor Specialist Hospital | Makkah | |
Saudi Arabia | Shifa Hospital | Makkah | |
Saudi Arabia | Al Zafer Hospital | Najran | |
Saudi Arabia | Alalam Medical Center | Riyadh | |
Saudi Arabia | Obesity, Endocrine and Metabolism Center | Riyadh | |
Saudi Arabia | Riyadh Medical Center | Riyadh | |
Saudi Arabia | Prince Fahad bin Sultan hospital | Tabuk | |
Saudi Arabia | Al Hada Armed Forces Hospital | Taif | |
Saudi Arabia | Al Amal Medical Group | Yanbu | |
Saudi Arabia | Alansari Specialist Hospital | Yanbu |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Ketoacidosis | Ketoacidosis is defined as a serious complication of diabetes characterized by high levels of ketones in the body due to lack of insulin and low food intake. | Up to 12 months after the index date (defined as the date on which each identified new user received the index prescription for Empagliflozin or DPP-4 inhibitor). | |
Primary | Number of Participants With Severe Urinary Tract Infections (UTIs) | Severe UTIs is defined as pyelonephritis or urosepsis. | Up to 12 months after index date (defined as the date on which each identified new user received the index prescription for Empagliflozin or DPP-4 inhibitor). | |
Primary | Number of Participants With Volume Depletion | Volume depletion is defined as the reduction in the extracellular fluids. | Up to 12 months after index date (defined as the date on which each identified new user received the index prescription for Empagliflozin or DPP-4 inhibitor). | |
Primary | Number of Participants With Dehydration | Dehydration is defined as the loss of total body water that leads to hypertonicity. | Up to 12 months after index date (defined as the date on which each identified new user received the index prescription for Empagliflozin or DPP-4 inhibitor). | |
Secondary | Number of Participants With Ketoacidosis During Ramadan Periods | Ketoacidosis is defined as a serious complication of diabetes characterized by high level of ketones in the body due to lack of insulin and low food intake.
Ramadan period is defined as the first day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar. The following Ramadan periods were included in this study: Ramadan month 2019: 5. May to 4. Jun 2019 (± 1 to 2 days) Ramadan month 2020: 23. April to 23. May 2020 (± 1 to 2 days). |
Up to day 29. | |
Secondary | Number of Participants With Severe Urinary Tract Infections (UTIs) During Ramadan Periods | Severe UTIs is defined as pyelonephritis or urosepsis.
Ramadan period is defined as the first day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar. The following Ramadan periods were included in this study: Ramadan month 2019: 5. May to 4. Jun 2019 (± 1 to 2 days) Ramadan month 2020: 23. April to 23. May 2020 (± 1 to 2 days). |
Up to day 29. | |
Secondary | Number of Participants With Volume Depletion During Ramadan Periods | Volume depletion is defined as the reduction in the extracellular fluids.
Ramadan period is defined as the first day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar. The following Ramadan periods were included in this study: Ramadan month 2019: 5. May to 4. Jun 2019 (± 1 to 2 days) Ramadan month 2020: 23. April to 23. May 2020 (± 1 to 2 days). |
Up to day 29. | |
Secondary | Number of Participants With Dehydration During Ramadan Periods | Dehydration is defined as the loss of total body water that leads to hypertonicity.
Ramadan period is defined as the first day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar. The following Ramadan periods were included in this study: Ramadan month 2019: 5. May to 4. Jun 2019 (± 1 to 2 days) Ramadan month 2020: 23. April to 23. May 2020 (± 1 to 2 days). |
Up to day 29. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |